Food and Drug Administration for ARM210.
The financing award to ARMGO Pharma comes from MDA Venture Philanthropy , part of MDA's translational research plan. Related StoriesFlorida Institute finalizes funding agreement with Genetic NetworksTesting amniotic fluid could guide doctors to make delivery planning decisions for preterm birthsDisclosing genetic risk for CHD results in lower low-density lipoprotein cholesterol DMD is one of nine types of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Sapan Shah , CEO and President of ARMGO Pharma.’.. ARMGO Pharma gets $1 million to aid ARM210 preclinical work for DMD treatment ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S.‘ A debate will end up being held on the very real and controversial topic of psychological distress. Experts will give their arguments on the pros and cons of screening individuals and delegates will become encouraged to contribute their views. Journalists will get both relative sides of the tale in a lively conversation which highlights the potential outcomes of screening. You will have a stronger focus on clinical abilities. Dr Hamilton said: ‘Communication between nurses, patients and families is key to nurses. Sessions will address communicating cardiovascular risk, patients' knowledge of their diagnosis, how to break bad information, pain management after surgery, and motivational interviewing.’ The congress theme is ‘Guidelines: Care to put into action’.